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The ABC transporter MsbA interacts with lipid A and amphipathic
drugs at different sites
Alena SIARHEYEVA and Frances J. SHAROM1
Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada N1G 2W1
MsbA is an essential ABC (ATP-binding cassette) transporter
involved in lipid A transport across the cytoplasmic membrane of
Gram-negativebacteria.Theproteinhasalsobeenlinkedtoefﬂux
of amphipathic drugs. Puriﬁed wild-type MsbA was labelled
stoichiometrically with the ﬂuorescent probe MIANS [2-(4
 -
maleimidylanilino)naphthalene-6-sulfonic acid] on C315, which
is located within the intracellular domain connecting transmem-
brane helix 6 and the nucleotide-binding domain. MsbA–MIANS
displayed high ATPase activity, and its folding and stability were
unchanged. The initial rate of MsbA labelling by MIANS was
reduced in the presence of amphipathic drugs, suggesting that
binding of these compounds alters the protein conformation. The
ﬂuorescenceofMsbA–MIANSwassaturablyquenchedbynucle-
otides,lipidAandvariousdrugs,andestimatesoftheKd valuesfor
bindingfellintherangeof0.35–10 μM.LipidAanddaunorubicin
wereabletobindtoMsbA–MIANSsimultaneously,implyingthat
they occupy different binding sites. The effects of nucleotide and
lipid A/daunorubicin binding were additive, and binding was not
ordered. The Kd of MsbA for binding lipid A was substantially
decreased when the daunorubicin binding site was occupied ﬁrst,
and prior binding of nucleotide also modulated lipid A binding
afﬁnity. These results indicate that MsbA contains two substrate-
binding sites that communicate with both the nucleotide-binding
domain and with each other. One is a high afﬁnity binding site for
the physiological substrate, lipid A, and the other site interacts
with drugs with comparable afﬁnity. Thus MsbA may function as
both a lipid ﬂippase and a multidrug transporter.
Key words: ATP-binding cassette (ABC) superfamily, daunoru-
bicin, ﬂuorescence labelling, lipid A, MsbA, substrate binding.
INTRODUCTION
The ABC (ATP-binding cassette) transporters are a large super-
family of proteins involved in membrane transport of a wide vari-
ety of compounds [1–3]. Among their substrates are amphipathic
drugs, bile salts, linear and cyclic peptides, steroids, detergents,
ﬂuorescent dyes, ionophores and lipids. The prototypical Gram-
negative bacterium Escherichia coli possesses approx. 80 ABC
proteins, accounting for almost 5% of its genome, most of which
areinvolvedinsoluteimport/export.MsbAwasinitiallyidentiﬁed
asamembrane-boundATPasein Gram-negativebacteriathat was
involved in lipid A export [4–6]. Depletion or loss of function
of MsbA results in the accumulation of LPS (lipopolysaccharide)
andphospholipidsinthecytoplasmicmembraneofE.coli[4,5,7].
MsbAisthuspresumedtotranslocatelipidA(andpossiblycertain
phospholipids) from the inner to the outer leaﬂet of the cytoplas-
mic membrane, although it is not required for phospholipids to
reach the outer membrane. However, it has never been directly
demonstratedthatMsbAiscapableofpromotingﬂip-ﬂopoflipids
in an ATP-dependent manner [8,9]. Multiple copies of msbA-like
genes have been identiﬁed in many bacterial genomes, whereas
lipid A is found only in Gram-negative bacteria, thus suggesting
that MsbA might also be involved in the transport of other
substrates[6].MsbAishomologous(∼30%sequenceidentity)to
bacterialLmrAfromLactococcuslactisandhumanPgp(P-glyco-
protein; ABCB1), both of which are drug efﬂux pumps causing
MDR (multidrug resistance) [10,11], and functional studies in
intactcellssuggestthatitcanalsotransportmultipledrugs[12,13].
LmrA can functionally substitute for a temperature-sensitive
MsbA mutant in E. coli WD2 at non-permissive temperatures
[12], and when expressed in L. lactis, MsbA confers resistance
to certain antibiotics, and displays Hoechst 33342 and ethidium
transport that can be inhibited by lipid A and vinblastine [13].
MsbA is a ‘half-transporter’, comprising a TM (transmem-
brane) domain with 6 membrane-spanning helices, which are
believedtocontainthesubstrate-bindingsite,andaNBD(nucleo-
tide-binding domain), for a total molecular mass of 64.5 kDa
[4–7] (Figure 1A). The functional MsbA transporter is presumed
to be a homodimer. Substrate transport is driven by the energy
provided by ATP hydrolysis, therefore interaction between the
NBDs and the TM domains is essential. Puriﬁed MsbA displays
basal ATPase activity that can be modulated by phospholipids
and a variety of lipid A species [7,14].
Following the retraction of high resolution X-ray crystallo-
graphic structures of three closely-related MsbA orthologues, re-
interpreted structural models based on the original data appeared
recently [15]. The structure of Salmonella typhimurium MsbA
with bound nucleotide shows a close association of the two
NBDs to form a ‘sandwich dimer’ of the type previously
observed for other isolated NBD subunits [16,17] and intact
prokaryotic ABC transporters [18–20], and may represent
a ‘closed’ inward-facing conformation. The six TM helices
in each MsbA monomer extend into the cytosol, forming
an ICD (intracellular domain) that may play a role in
coupling ATP hydrolysis to substrate transport. In contrast,
the 5.3 Å (1 Å=0.1 nm) resolution structure of E. coli MsbA
in the absence of nucleotide shows a 50 Å separation between the
NBDs of the two monomers, and was proposed to represent an
“open” inward-facing conformation of the transporter. However,
it is possible that this atypical dimeric structure represents a crys-
tallization artefact, since it seems unlikely that an ABC protein
wouldundergosuchalargemovementduringeachcatalyticcycle.
Abbreviations used: ABC, ATP-binding cassette; ATP[S], adenosine 5 -[γ-thio]triphosphate; DM, n-dodecyl-β-D-maltoside; DTE, dithioerythritol;
ICD, intracellular domain; MALDI–TOF, matrix-assisted laser-desorption ionization–time-of-ﬂight; MDR, multidrug resistant/resistance; MIANS, 2-
(4 -maleimidylanilino)naphthalene-6-sulfonic acid; NBD, nucleotide-binding domain; Ni-NTA, Ni2+-nitrilotriacetate; PC, phosphatidylcholine; Pgp,
P-glycoprotein; p[NH]ppA, adenosine 5 -[β,γ-imido]triphosphate; TM, transmembrane.
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Figure 1 Topology and puriﬁcation of MsbA
(A) Topological model of the MsbA protein. Each monomer contains 6 membrane-spanning helices forming a TM domain, with the NBD at the C-terminal end. Amino acid residues are
indicated inside the circles; endogenous cysteine residues are numbered. The dotted box represents the TM domain boundaries of MsbA determined by EPR spectroscopy [21]. The X-ray crystal
structure of Salmonella typhimurium MsbA (PDB: 3b60 [15]) suggests the following membrane-spanning domain boundaries: 1(27–52), 2(62–87), 3(142–163), 4(165–182), 5(248–271) and
6(283–305). The solid box represents the predicted TM domain boundaries (http://www.expasy.org/uniprot/P60752). (B) Puriﬁcation of MsbA from cytoplasmic membrane vesicles of E. coli
overexpressing the protein. Lane 1, SDS/PAGE analysis of puriﬁed MsbA (1μg) in 0.05% (w/v) DM, stained with Coomassie Blue; lane 2, Western blot of puriﬁed MsbA using an anti-His6
antibody.
Additional structural information on MsbA comes from EPR
spectroscopicstudies[21–25].Borbatetal.[25]recentlyproposed
that a large change in the separation of the NBDs takes place
during the dimerization–dissociation cycle of the E. coli protein.
The available biochemical and dynamic information for this
interesting protein is still very limited, and its transport substrates
remain poorly deﬁned. Among various biophysical methods for
studying protein structure and dynamics, ﬂuorescence spectro-
scopy is especially valuable for monitoring protein conforma-
tional changes induced by ligand binding. Recent work in our
laboratory has employed the intrinsic Trp ﬂuorescence of MsbA
to characterize the binding of nucleotides and putative transport
substrates, including lipid A [14]. Fluorescent probes targeted
to Cys residues are also very useful, and have been used to
study a variety of active transporters, including lactose permease,
MalFGK2,P g p ,t h eC a
2+- A T P a s ea n dt h eN a
+/K
+-ATPase.
In the present study, we used puriﬁed MsbA labelled on Cys
315
with the environmentally sensitive ﬂuorescent probe MIANS [2-
(4
 -maleimidylanilino)naphthalene-6-sulfonic acid] [26,27].
Using ﬂuorescence quenching, we observed simultaneous high
afﬁnity binding to MsbA of lipid A (the putative physiological
substrate) and daunorubicin, which suggests that the protein
has separate binding sites for these two compounds. The effects
of nucleotide and lipid A/daunorubicin binding to MsbA were
additive, and binding could occur in any order. The two substrate-
binding sites appear to communicate with each other, and also
with the nucleotide-binding site in the NBDs, as indicated by
alterations in the binding afﬁnity at one site when one of the
others is occupied. Characterization of these substrate-binding
processes is an essential ﬁrst step towards understanding the
catalytic/transport cycle of MsbA.
EXPERIMENTAL
Materials
Acrylamide, ammonium persulfate, Coomassie Brilliant Blue,
and molecular mass standards were purchased from Bio-Rad
Laboratories. PVDF electroblotting membrane was from Milli-
pore. MIANS was purchased from Molecular Probes. The pro-
pafenone compound GP12 [28] was a gift from Dr Peter Chiba
(Department of Medicinal Chemistry, University of Vienna,
Austria). Other drugs and lipid A (diphosphoryl, from E. coli
F583; Rd mutant) were obtained from Sigma-Aldrich. DM
(n-dodecyl-β-D-maltoside) was purchased from Alexis Bio-
chemicals. Egg PC (phosphatidylcholine) was purchased from
Avanti Polar Lipids. Biobeads were supplied by Bio-Rad
Laboratories. All other reagents were of analytical grade.
MsbA mutagenesis and expression
The pET28b vector (Novagen) containing the msbA gene with an
N-terminal His6 tag was described previously in [22]. Both native
cysteine residues (Cys
88 and Cys
315) were substituted with serine
by site-directed mutagenesis using the QuikChange mutagenesis
kit (Stratagene). For the substitution of Cys
315 with serine,
3
 -CGCGGTATGGCGGCTTCCCAGACGCTGTTTACCATT-5
 
and 5
 -AATGGTAAACAGCGTCTGGGAAGCCGCCATACC-
GCG-3
  wereusedastheforwardandreverseprimersrespectively.
For the substitution of Cys
88 with serine, the forward and reverse
primers were 3
 -ATGTCTCCAGCTACTCCATCTCCTGGGTA-
TCAGGA-5
  and 5
 -TCCTGATACCCAGGAGATGGAGTAGC-
TGGAGACATA-3
  respectively. All primers were obtained
from Invitrogen. Mutant plasmids were sequenced in full to
verify the introduced mutations. The plasmids containing the
wild-type and mutated msbA genes were transformed into
BL21-Codonplus(DE3)-RIL competent cells (Stratagene). Cells
cultured overnight at 37◦C in Luria–Bertani broth, supplemented
with 30 μg/ml kanamycin, were used to inoculate a large-scale
culture in fresh medium. Cells were grown at 37◦C until the
attenuance (D600) reached approx. 1, and MsbA overexpression
was induced by the addition of 1 mM IPTG (isopropyl β-D-
thiogalactoside). Growth was continued at 37◦C for 3 h, and
cells were harvested by centrifugation at 7000 g for 15 min
at 4◦C.
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MsbA puriﬁcation
Cell pellets were resuspended in 100 mM Hepes, 500 mM NaCl
and 5 mM MgCl2, pH 7.5, and passed through a French pressure
cell disrupter at 1000 p.s.i. (1 p.s.i.=6.9 kPa). Cell debris was
removed by centrifugation at 15000 g for 20 min at 4 ◦C. For
puriﬁcation of His-tagged wild-type MsbA and mutants C88S
and C315S, the resulting membranes were treated on ice with
solubilization buffer [20 mM Hepes, 100 mM NaCl and 1.1%
(w/v) DM, pH 8.0] for 1 h. All further steps were carried out at
4 ◦C. Unsolubilized material was removed by ultracentrifugation
(171500 g, 30 min), and the supernatant was incubated for 1 h on
ice with Ni-NTA (Ni
2+-nitrilotriacetate) agarose pre-equilibrated
with buffer A [20 mM Hepes, 100 mM NaCl and 0.05% (w/v)
DM, pH 8.0] containing 10 mM imidazole. After incubation, the
resin was packed into a column and contaminating proteins
were washed off with buffer A and buffer B [20 mM Hepes,
100 mM NaCl and 0.05% (w/v) DM, pH 7.0] containing 10 mM
imidazole. When no further protein was detected in the ﬂow-
through (monitored at 280 nm), MsbA was eluted with buffer
B supplemented with 250 mM imidazole. Fractions containing
MsbA were pooled and concentrated to ∼1 mg/ml. MsbA purity
was monitored by SDS/PAGE analysis and Coomassie Blue
staining, as well as by Western blotting after transfer to a nitro-
cellulose membrane. The blot was probed with mouse anti-His6
antibody (Qiagen), followed by goat anti-mouse IgG-horseradish
peroxidase conjugate, and bands were detected using the ECL®
(enhanced chemiluminescence) detection system (Amersham).
MsbA was reconstituted into proteoliposomes using detergent
destabilization [29]. Egg PC, at an initial molar ratio of 300 lipids
per protein, was suspended in Hepes buffer (20 mM Hepes,
100 mM NaCl and 5 mM MgCl2, pH 7.4) at a concentration of
4 mg/ml. The lipid suspension was extruded 11 times through
a 400 nm polycarbonate ﬁlter (Whatman) using an extrusion
device (Avestin). The liposome suspension was then titrated with
a DM solution to a concentration of 0.15% (w/v) and mixed
with DM-solubilized concentrated MsbA (Centricon YM-50).
The detergent-destabilized liposomes and puriﬁed protein were
incubated for 30 min at 23◦C, Biobeads were added to a ﬁnal
concentration of 80 mg/ml, and the mixture was incubated
for a further 1 h at 4 ◦C. After removal of the Biobeads, the
proteoliposomes were pelleted by centrifugation (190000 g for
30 min at 4◦C). The proteoliposome protein concentration was
measured using a modiﬁed Lowry assay [30]. The recovery of
MsbA in the reconstituted proteoliposomes was ∼85%,a n dt h e
ATPase activity of the proteoliposomes was increased by approx.
50% following addition of a permeabilizing concentration of
detergent (15 mM CHAPS). This suggests that ∼2/3 of the
reconstitutedMsbAfacesinwards(NBDsonthevesicleexterior),
and ∼1/3 faces outwards (NBDs in the vesicle lumen).
ATPase activity assay
Puriﬁed wild-type MsbA and the C88S and C315S mutants
[∼100 μg/ml in 0.05% (w/v) DM] were assayed for ATPase
activity using a colorimetric assay that measures the liberation
of free Pi from ATP [31]. To determine the inﬂuence of
various concentrations of ATP on MIANS-labelled MsbA, the
ATPase activity was determined following labelling. Unreacted
MIANS was quenched with 1 mM DTE (dithioerythritol) before
measuring ATPase activity.
Site-speciﬁc MIANS labelling of MsbA
Puriﬁed MsbA (wild-type, MsbA-C88S and MsbA-C315S) was
incubated with 10 μM MIANS for 2 h at room temperature
(23◦C) in the dark. Unreacted MIANS was quenched with 1 mM
DTE and the excess label was removed by dialysis overnight
against Hepes buffer. The ﬁnal concentration of MIANS-labelled
MsbA used for ﬂuorescence measurements was 100 μg/ml.
Fluorescence measurements
Fluorescence spectra were recorded at 23◦Cu s i n gaP T I
QuantaMaster C-61 steady-state ﬂuorimeter (Photon Technology
International). Emission spectra were recorded after excitation at
322 nm (4 nm slits). As a control, MIANS was reacted with DTE.
To estimate the time needed for complete MIANS labelling of
MsbA, 10 μM MIANS was added to the protein [100 μg/ml in
0.05% (w/v) DM] and the reaction was followed continuously
in real time at an emission wavelength of 420 nm. Intrinsic
ﬂuorescence spectra of MsbA and MsbA–MIANS were recorded
with selective excitation of tryptophan residues at 290 nm, and
also after denaturation of the proteins for 15 min at 90◦C with
6 M guanidine hydrochloride.
To determine how drugs and lipid A modulated MIANS
labelling, 70 μg/ml MsbA in Hepes buffer containing 0.05%
(w/v) DM was preincubated with the test compound for 15 min at
23 ◦C. Each compound was used at a ﬁnal concentration approx.
5-fold higher than its estimated Kd for binding to the protein, as
determined by MIANS ﬂuorescence quenching (see Table 2), to
ensure that saturation was approached. Labelling was initiated by
adding MIANS (20 μM) and ﬂuorescence emission intensity at
420 nmwasmonitoredcontinuously(0.2 sintervals),withexcita-
tionat322 nm,fortimesupto2000 s.Initialratesoflabellingwere
measured from the linear rate of ﬂuorescence intensity increase
observed over the ﬁrst 20 s after addition of MIANS.
Stoichiometry of MIANS labelling
Unlabelled and MIANS-labelled MsbA were transferred from
high-salt to low-salt buffer using gel ﬁltration chromatography
on a 10 ml desalting column (Bio-Rad Laboratories). The
samples were then lyophilized and redissolved in 6 M guanidine
hydrochloride. The ﬁnal protein concentration was determined
using a modiﬁed Lowry assay [30] with bovine serum albumin as
a standard, and adjusted to 350 μg/ml for both samples. The ab-
sorbance values from the protein assay were corrected for the
presenceofMIANS.Theabsorptionspectraofbothsampleswere
recorded using a UV/visible spectrophotometer. To estimate the
stoichiometry of labelling, the extinction coefﬁcient of MIANS
was taken as 27000 cm
−1 ·M
−1 (Molecular Probes) and the molar
mass of MsbA was assumed to be 65 kDa.
MS
MALDI–TOF (matrix-assisted laser-desorption ionization–time-
of-ﬂight) MS was used to determine which cysteine residues in
MsbA were labelled by MIANS. Puriﬁed MsbA was digested
with chymotrypsin (sequence grade; Roche Diagnostics) at 30◦C
for 24 h, incubating 10 μg of protein per μgo fp r o t e a s ei na2 0μl
volume. MALDI–TOF was performed using a Bruker-Relex
(Bruker-Franzen Analytik). The MIANS-labelling site of MsbA
was identiﬁed by comparing the actual mass of the individual
peptides from MALDI–TOF analysis with the predicted mass of
the corresponding peptides obtained from the ExPASy peptide
massanalysistool(http://ca.expasy.org/tools/peptide-mass.html).
CD spectroscopy
Prior to CD measurements, unlabelled MsbA and MsbA–MIANS
were transferred to phosphate buffer (10 mM phosphate and
100 mM NaF, pH 7.0) supplemented with 0.01% (w/v) DM by
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gelﬁltrationona10 mldesaltingcolumn(Bio-RadLaboratories).
CDmeasurementswereperformedusingaJascoJ-810instrument
equipped with an external water bath. The thermal stability of
MsbA secondary structure was monitored by heating 350 μg/ml
samples over the range 20–65 ◦C. The mean residue ellipticity
was recorded at 5◦C intervals over the range 195–275 nm at a
scanning rate of 100 nm/min. Four scans were accumulated at
each temperature. The data pitch was 0.1 nm, the response time
was 0.5 s and band width was 1 nm. CD spectra were corrected
for the solvent CD signal recorded from 20–65 ◦C. Secondary
structure analysis was carried out using the DICHROWEB server
(http://www.cryst.bbk.ac.uk/cdweb/html/home.html).
Fluorescence quenching studies
Fluorescence quenching experiments with nucleotides (except
ATP), drugs and lipid A were carried out at 23◦Cu s i n g
250 μl of MsbA (100 μg/ml) in 100 mM Hepes, 50 mM NaCl,
5m MM g C l 2 and 0.05% (w/v) DM, pH 7.5. Experiments with
ATP were carried out at 10◦C to prevent hydrolysis during the
experiment.WorkingsolutionswerepreparedinDMSOfordrugs
and in the 100 mM Hepes, 50 mM NaCl and 5 mM MgCl2 buffer
for nucleotides. Lipid A was resuspended at a concentration of
0.5 mg/ml (molecular weight 1.7–1.8 kDa) in 20 mM Hepes,
pH 7.5. To quench the MIANS ﬂuorescence, MsbA–MIANS
samplesweretitratedwithvarioussubstrates.Aftereachaddition,
the samples were allowed to reach steady-state for 1 min and the
ﬂuorescence was measured at 420 nm. Fluorescence intensities
were corrected for dilution, scattering, and the inner ﬁlter
effect as described previously [32,33]. Fluorescence changes
were routinely expressed as the percent change in ﬂuorescence
intensity at 420 nm induced by substrate relative to the intensity
measured in the absence of substrate. Experimental data were
computer-ﬁtted to the following equation:

 F
F0

× 100 =
( Fmax/F0 × 100)[S]
Kd + [S]
where F0 is the initial value of ﬂuorescence intensity,  F is the
change in ﬂuorescence intensity at a given point in the titration,
( F/F0 ×100)isthepercentquenchingatsubstrateconcentration
[S], ( Fmax/Fo ×100) is the maximal percent quenching and Kd
is the dissociation constant. Fitting to a single-site model was
carried out using nonlinear regression (Sigmaplot 10.0, Systat
Software), and values for Kd and  Fmax were estimated.
Double titration experiments were performed in essentially
the same way, the only difference being that MsbA–MIANS
was titrated ﬁrst with one substrate, and then with a second. For
lipid A/daunorubicin binding, as well as p[NH]ppA (adenosine
5
 -[β,γ-imido]triphosphate)/lipid A or ATP/lipid A binding, the
titrations were performed in each of two possible sequences.
Each titration point was corrected for the inner ﬁlter effect,
scattering, and dilution.
RESULTS
Puriﬁcation of MsbA
MembranevesicleswereisolatedfromE.colicellsoverexpressing
His6-tagged wild-type MsbA and the two site-directed mutants,
C88S and C315S. After membrane solubilization in DM, MsbA
puriﬁcation was carried out using Ni-NTA chromatography.
The fractions containing puriﬁed protein were pooled and
concentrated, to yield approx. 1 mg of MsbA from 15 mg of
membrane protein. Analysis using SDS/PAGE and Western
blottingshowedthatMsbAwasisolatedathighpurity(Figure1B),
Figure 2 Catalytic activity of MsbA and MsbA–MIANS
(A) The ATPase activity at 37◦C as a function of ATP concentration for MsbA–MIANS ()a n d
unlabelled MsbA (). Data points are the means+ −S.D. (n=3). In both cases, puriﬁed MsbA
was in a buffer containing 0.05% (w/v) DM. (B) Hill plot of the ATPase activity of wild-type
MsbA () and MsbA–MIANS () as a function of ATP concentration; MsbA Hill coefﬁcient,
n=1.03+ −0.03, MsbA–MIANS Hill coefﬁcient, n=1.01+ −0.03.
with an ATPase-speciﬁc activity of 400+ −5 nmol/min per mg of
protein (at 2 mM ATP) for wild-type protein. The ATPase activity
of the C88S and C315S mutants did not differ substantially from
that of wild-type MsbA. The ATPase activity of wild-type MsbA
was measured for a range of ATP concentrations from 0.05–
10 mMat4,23and37◦C(resultsfor37◦CareshowninFigure2).
Activity increased in a hyperbolic fashion with increasing ATP
concentration, and levelled off above 1.5 mM ATP (Figure 2A).
SimilarATPaseactivitydependenceonATPconcentrationwasre-
ported previously [4,7]. The Km for unlabelled MsbA was 0.52+ −
0.04 mM,whereasforMIANS-labelledprotein(seebelow)itwas
0.41+ −0.04 mM. The corresponding Vmax values were 418+ −12
and 354+ −13 nmol/min per mg of protein, for unlabelled and
MIANS-labelled MsbA respectively. We previously reported that
puriﬁed MsbA is homodimeric in DM solution [14]. When
the kinetic data for wild-type and MIANS-labelled MsbA
were ﬁtted to the Hill equation, coefﬁcients close to 1 were
obtained (Figure 2B), suggesting that the two monomers function
independently, and do not interact co-operatively with each other.
This is consistent with the “alternating sites” proposal of Senior
etal.[34]forthemechanismofPgp,whichisalsoproposedtobea
dual drug transporter and lipid ﬂippase; only one NBD is thought
to be active at any instant in time, and the two sites alternate in
catalysis.
Site-speciﬁc labelling of MsbA with MIANS
MIANS has been widely used as a cysteine-reactive ﬂuorescent
probe for soluble and membrane-bound proteins. Its quantum
yield and emission maximum are highly sensitive to the polarity
of its local environment [26,27]. MsbA labelling was performed
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Figure 3 Reaction of wild-type and cysteine mutant MsbA proteins with
MIANS
Time-dependent reaction of wild-type MsbA (MsbA-WT) and the site-directed mutants
MsbA-C88SandMsbA-C316SwithMIANS.MIANSlabellingofMsbA(100μg/ml)wascarried
outinbuffercontaining0.05%(w/v)DM.Labellingwasinitiatedbyadditionof10μMMIANS,
and ﬂuorescence emission was recorded continuously at 420nm (λex =322nm).
under non-denaturing conditions with a 15-fold molar excess of
the ﬂuorophore, and yielded highly labelled protein after removal
of free label by dialysis. As shown in Figure 1(A), MsbA has two
nativecysteineresidues,one(Cys
88)atthecytoplasmicendofTM
helix2,andone(Cys
315)intheICDconnectingtheC-terminalend
ofTMhelix6totheNBD,asindicatedbybothEPRspectroscopy
[21] and X-ray crystallography [15]. MsbA–MIANS retained an
ATPase activity of 354 nmol/min per mg of protein (Vmax)a f t e r
labelling, approx. 15% lower than native MsbA, indicating that
activity is almost fully retained after labelling. The addition of
0.05–2 mM ATP did not protect MsbA from this small activity
loss during labelling. This is perhaps not surprising, since both
cysteine residues are expected to be distant from the ATP-binding
site within the NBD (the catalytic site is located approx. 60
residues from Cys
315 and 287 residues from Cys
88).
Stoichiometry of MIANS labelling
The calculated labelling stoichiometry was found to be
approximately one MIANS molecule per one MsbA monomer, as
estimated using the extinction coefﬁcient of bound MIANS. One
cysteine residue within each MsbA monomer could be modiﬁed
with a labelling level of 100%, but another possibility is that
both cysteine residues are labelled, but to a lower extent. Partial
labelling seems unlikely, since the molar ratio of label to protein
is approx. 15:1, and MIANS is highly reactive. Cysteine residues
within the TM regions of integral proteins are often highly
resistanttolabelling.Forexample,cysteineresiduesburiedwithin
theTMdomainofPgpwereessentiallycompletelyinaccessibleto
covalent modiﬁcation by MIANS [32]. We might expect Cys
315
to be more readily labelled than Cys
88, which is located close to
the membrane boundary at the cytoplasmic end of TM helix
2. MALDI–TOF experiments on unlabelled MsbA and MsbA–
MIANS conﬁrmed that this was indeed the case. The Cys
315
residue of MsbA was fully modiﬁed with MIANS, since m/z of
theQRGMAACQTLFpeptidefragmentincreasedfrom1225.582
to 1641.438, and the difference in m/z of 416 corresponds to the
molecularmassofMIANS(416.38Da).MIANSlabellingexperi-
ments were also carried out with site-directed mutants in which
Cys
88 and Cys
315 were each replaced by serine. As shown in Fig-
ure 3, MsbA-C88S reacted with MIANS at the same rate and to
a similar extent to the wild-type protein, whereas MsbA-C315S
Figure 4 Fluorescence emission spectra of MsbA and MsbA–MIANS
(A) Fluorescence emission spectra of MIANS (λex =322nm) covalently linked to MsbA
(continuousline)andtothesolublecompoundDTE(brokenline).(B)IntrinsicTrpﬂuorescence
emission spectra (λex =290nm) of MsbA–MIANS (short-dashed line and long-dashed line)
and unlabelled MsbA (continuous line and dotted line) before and after, respectively, treatment
with 6 M guanidine hydrochloride (GuHCl).
showedaverylowbackgroundrateofreaction.Theseresultscon-
ﬁrm that Cys
315 is the primary site of MIANS labelling in MsbA.
Fluorescence spectra of MsbA–MIANS
MIANS covalently linked to Cys
315 in MsbA displayed an
emission maximum, λem,o f∼423 nm, whereas the λem for
MIANS following reaction with the soluble compound DTE was
448 nm (Figure 4A). This large blue shift of ∼25 nm indicates
that Cys
315 is located in a relatively nonpolar environment. The
MsbA–MIANS ﬂuorescence spectrum displayed a homogeneous
shape,withthesamespectralwidthasMIANS–DTE(Figure4A),
indicating that the labelled cysteine residues are located in a
similar environment in the homodimer, as expected. The intrinsic
tryptophan ﬂuorescence spectrum of MsbA showed a λem of
328 nm (Figure 4B), which was substantially blue-shifted re-
lative to the λem for the soluble Trp analogue, N-acetyl-
tryptophanamide (356 nm; [35]). An almost identical tryptophan
emission spectrum was observed for MsbA–MIANS. After
heating with 6 M guanidine hydrochloride, both unlabelled
MsbA and MsbA–MIANS displayed a substantial red shift in
theiremissionmaximato335and337 nmrespectively,consistent
with partial unfolding of the protein. Thus, MIANS-labelled
MsbA behaves very similarly to the native protein, suggesting
that its tertiary structure and folding are unaltered.
Secondary structure of MsbA
The CD spectra of native MsbA and MsbA–MIANS were
essentially superimposable (Figure 5A), indicating that covalent
linkage of MIANS does not perturb the overall protein secondary
structure. Analysis of the CD spectrum using the DICHROWEB
server [36] indicated that MsbA comprises 58% α-helix, 9%
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Figure 5 CD spectroscopy of MsbA and MsbA–MIANS
(A) CD spectra of unlabelled MsbA (continuous line) and MsbA–MIANS (dotted line) at a
concentration of 0.35mg/ml in buffer with 0.01% (w/v) DM. (B) Thermal unfolding of MsbA
and MsbA–MIANS monitored by CD spectroscopy. CD measurements were carried out on
puriﬁedunlabelledMsbA()andMsbA–MIANS()ataconcentrationof0.35mg/mlinbuffer
with 0.01% (w/v) DM. Molar ellipticity was recorded at 222nm, which reports on α-helical
unfolding.
β-strand and 34% random coil/unassigned structure (8%
maximum error). These data are in good agreement with X-ray
structures reported for MsbA from three bacterial species [15],
where α-helices make up a large proportion of the secondary
structure (63% α-helix, 10% β-strand; http://www.rcsb.org).
The conformational stability of proteins can be assessed by
thermal or chemical denaturation, which can be monitored by CD
spectroscopy [37]. Thermal denaturation of native and MIANS-
labelled MsbA resulted in CD spectral changes from 195–275 nm
indicative of a coincident decrease in both secondary and tertiary
structure. Figure 5(B) shows the temperature-induced CD change
inMsbAat222 nm,whichwaschosenbecauseellipticitychanges
atthiswavelengthreﬂectalterationsinα-helicalcontent[38].The
thermally-induced changes in secondary structure for both native
and MIANS-labelled MsbA are essentially identical, showing
that they unfold to the same extent, and with the same rate and
temperature dependence. Thus, the folding and stability of MsbA
is essentially unaltered after covalent attachment of MIANS.
Drugs and lipid A modulate MIANS labelling of MsbA
WhenMIANSreactscovalentlywithcysteineresidues,itbecomes
highlyﬂuorescent.Wemadeuseofthispropertytodetectchanges
in labelling of MsbA upon binding of putative substrates, by
followingthereactionwithMIANSinrealtime.Thus,additionof
MIANS to puriﬁed MsbA led to a rapid increase in ﬂuorescence
emission intensity (Figure 6A). In the absence of substrates,
MIANS labelling displayed the maximal rate (Figure 6A, trace 1)
and complete labelling of MsbA was achieved in ∼15 min at
23 ◦C.Suchafastreactionrateistypicalwhenthe-SHgroupisthe
target of MIANS labelling. When MsbA was preincubated before
Figure 6 Rate of reaction of MsbA with MIANS in the presence of drugs and
lipid A
MIANS labelling of MsbA (70μg/ml) was carried out in buffer containing 0.05% (w/v) DM.
MsbAwaspreincubatedfor15minat23◦CwithvariousdrugsandlipidAatconcentrations(see
Table 1) corresponding to ∼5-fold higher than their Kd for binding (see Table 2). (A) Labelling
was initiated by adding MIANS (20μM) and ﬂuorescence emission intensity ﬂuorescence
emissionwasrecordedcontinuously(0.2 sintervals)at420nm(λex =322nm),fortimesupto
2000s. (B) Initial rates of labelling were observed over the ﬁrst 20s after addition of MIANS. 1,
MsbA in the absence of drug; 2, 6 μM vinblastine; 3, 40μM quercetin; 4, 6 μM verapamil; 5,
2 μMvalinomycin;6,30μMlipidA;7,4 μMpropafenoneGP12;and8,25μMdaunorubicin.
addition of MIANS with lipid A and various amphipathic drugs
known to be substrates for MDR transporters, both the initial
rate of increase in ﬂuorescence (measured over the ﬁrst 20 s) and
the ﬂuorescence intensity reached after 15 min were reduced, in
some cases substantially (Figures 6A and 6B). Each drug was
tested at an approximately saturating concentration (estimated as
∼5-fold higher than the Kd for binding; see Tables 1 and 2). Of
the drugs tested, the initial rate of MIANS labelling (measured
over the ﬁrst 20 s) was affected the least by vinblastine, and the
most by daunorubicin (Figure 6B and Table 1). Determination of
the extent of MIANS labelling of MsbA in the presence of each
drug showed that the labelling efﬁciency was ∼80% or more in
all cases (Table 1). Overall, these results suggest that binding of
drugs and lipid A to MsbA appears to alter the accessibility or
reactivity of Cys
315 to labelling with the ﬂuorophore.
Quenching of MsbA–MIANS by drugs and nucleotides
MIANS ﬂuorescence quenching experiments were carried
out on puriﬁed MsbA–MIANS in 0.05% (w/v) DM buffer.
Saturable concentration-dependent quenching of MsbA–MIANS
ﬂuorescencewas observed onaddition of several drugs,including
valinomycin, vinblastine, verapamil, daunorubicin and quercetin
(Figure 7), nucleotides (Figure 8), and the putative physiological
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Table 1 Parameters for drug modulation of the rate of MsbA labelling by
MIANS
Labellingexperimentswerecarriedoutat23◦CbyaddingMIANS(20μM)toMsbA(70μg/ml)
in Hepes buffer containing 0.05% (w/v) DM, in the absence or presence of various drugs.
Fluorescence emission intensities were recorded continuously (every 0.2 s) for times up to
2000s. Initial rates of labelling were measured from the linear rate of ﬂuorescence intensity
increase observed over the ﬁrst 20s after addition of MIANS. The labelling efﬁciency was
determined after 2000s by measuring the MIANS:MsbA stoichiometry.
Concentration Initial rate of labelling
Drug (μM) (ms−1) Labelling efﬁciency (%)
Control (none) 313+ −6.3 105+ −4.5
Vinblastine 6 182+ −3.4 105+ −4.5
Quercetin 40 85.0+ −3.1 78.8+ −1.0
Verapamil 6 71.0+ −2.6 82.2+ −3.6
Valinomycin 2 66.8+ −3.4 101+ −3.2
Lipid A 30 65.5+ −2.5 118+ −9.2
Propafenone GP12 4 59.1+ −2.7 81.9+ −4.2
Daunorubicin 25 27.4+ −2.3 87.2+ −1.3
substrate, lipid A (Figure 9). The maximal percentage of quench-
ing depended on the particular compound, and varied from 6 to
60%(Table2),withthehighestquenchingnotedfordaunorubicin
and the lowest for ATP[S] (adenosine 5´ -[γ-thio]triphosphate).
No signiﬁcant shift in the λem for MsbA–MIANS was detected
in the presence of any of these compounds. To examine MsbA
interactions with drugs and nucleotides quantitatively, analysis
of the ﬂuorescence quenching titration experiments was carried
out. For all drugs and nucleotides tested, the change in MIANS
ﬂuorescence followed a hyperbolic curve and was monophasic
(Figures 7–9), which suggests the existence of only one binding
site, or possibly two binding sites of similar afﬁnity. Curve-
Table 2 Parameters for ﬂuorescence quenching of MsbA-MIANS by lipid A,
drugs and nucleotides
Fluorescence quenching experiments with lipid A, drugs and nucleotides (except ATP) were
carried out at 23◦C using MsbA (100μg/ml) in Hepes buffer containing 0.05% (w/v) DM.
Corrected ﬂuorescence emission intensities were ﬁtted to a single binding-site model using
non-linear regression, and values for Kd and  Fmax were estimated. *Experiments using ATP
were carried out at 10◦C to prevent hydrolysis of nucleotide.
Maximal quenching
Ligand Kd (μM) ( Fmax/F0 ×100) (%)
Lipid A 5.46+ −1.04 7.32+ −0.49
Amphipathic drugs
Valinomycin 0.35+ −0.04 6.67+ −0.11
Propafenone GP02 0.66+ −0.14 7.04+ −0.30
Vinblastine 1.20+ −0.14 18.6+ −0.50
Verapamil 1.26+ −0.09 17.6+ −0.30
Daunorubicin 4.60+ −0.20 59.9+ −4.4
Daunorubicin/egg PC 4.30+ −0.79 60.0+ −3.7
Quercetin 8.56+ −0.79 56.0+ −1.9
Nucleotides
ATP* 3050+ −430 10.9+ −0.75
p[NH]ppA 470+ −30 14.1+ −0.30
ATP[S] 1.82+ −0.29 6.01+ −0.20
ADP 130+ −60 8.48+ −0.4
AMP 800+ −200 7.84+ −0.80
ﬁtting was used to estimate the dissociation constant, Kd,a n dt h e
maximal percentage of quenching, ( Fmax/Fo ×100), for each
drug. The estimated Kd values obtained for amphipathic drugs
ranged from 0.35 to 8.56 μM (Table 2), and are comparable
with the afﬁnity estimated for the physiological substrate, lipid
A (5.46 μM). To test the effect of a lipid bilayer on MsbA drug
bindingafﬁnity,thepuriﬁedproteinwasreconstitutedintoeggPC
Figure 7 Quenching of MsbA–MIANS ﬂuorescence by drugs
Increasing concentrations of various drugs were added to 100μg/ml MsbA–MIANS in 0.05% (w/v) DM buffer at 23 ◦C. The ﬂuorescence emission was monitored at 420nm (λex =322nm). The
percent quenching of MsbA–MIANS ﬂuorescence ( F/F0 ×100) was calculated relative to the ﬂuorescence in the absence of drugs. The continuous line represents the best computer-generated
ﬁt of the data points to an equation describing interaction with a single type of binding site, and were used to estimate the Kd of binding. (A) quercetin, (B) valinomycin, (C) verapamil and
(D) vinblastine. Data points are the means+ −S.D. (n=3).
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Figure 8 Quenching of MsbA–MIANS ﬂuorescence by nucleotides
Increasing concentrations of nucleotides were added to 100μg/ml MsbA–MIANS in 0.05% (w/v) DM buffer at 23◦C (with exception of ATP, which was added to MsbA at 10◦C to prevent ATP
hydrolysis). The ﬂuorescence emission was monitored at 420nm (λex =322nm). The percent quenching of MsbA–MIANS ﬂuorescence ( F/F0 ×100) was calculated relative to the ﬂuorescence
in the absence of nucleotides. The continuous line represents the best computer-generated ﬁt of the data points to an equation describing interaction with a single type of binding site, and were used
to estimate the Kd of binding. (A)A T P ,( B)A M P ,( C)A D Pa n d( D)A T P [ S ]( A T P γS). Data points are the means+ −S.D. (n=3).
proteoliposomesbydetergentdestabilization.Thebindingafﬁnity
of daunorubicin was essentially the same for MsbA in DM buffer
and lipid bilayers (Table 2). The Kd for nucleotides varied from
0.13 to 3.5 mM, with the exception of ATP[S], which bound to
MsbA with a relatively high afﬁnity of 1.82 μM. ATP binding
was measured at 10◦C to avoid hydrolysis of the nucleotide. At
this temperature, the Kd of MsbA–MIANS for ATP binding was
>7-fold higher than that determined for the non-hydrolysable
analogue p[NH]ppA at 23◦C( T a b l e2 ) .
Sequential binding of lipid A, daunorubicin and nucleotides
to MsbA
To determine whether drug and lipid A molecules can bind to
MsbA simultaneously, dual titration experiments were carried
out, titrating the protein ﬁrst with lipid A and then with dauno-
rubicin. A separate experiment was then carried out with
the same substrates, but titrating them in the reverse order.
Figure 9(A) shows that MsbA–MIANS ﬂuorescence can be
quenched sequentially by lipid A and daunorubicin, implying
that both of these molecules can bind to MsbA simultaneously at
separate sites. The total MIANS quenching arising after binding
of both lipid A and daunorubicin was approximately equal to the
sum of the values observed for each species when added to
MsbA separately, indicating that their effects on the protein are
essentially additive. The percentage quenching values observed
for lipid A and daunorubicin were also similar regardless of the
orderoftitration.Interestingly,thebindingafﬁnityforlipidAwas
reduced∼5-foldat23◦C(Kd increasedfrom5.46to24.5 μM)and
∼7-fold at 10◦C( Kd increased from 2.44 to 18.1 μM) when the
daunorubicin-bindingsitewasoccupiedﬁrst(Table3,Figure9B).
The  Fmax for lipid A quenching also increased 2-fold when
daunorubicin was bound ﬁrst, indicating that conformational
changes take place at the lipid A binding site when the drug-
binding site is occupied. In contrast, pre-binding of lipid A did
not affect the daunorubicin binding afﬁnity at 23◦C, and led to
only a small (∼2-fold) reduction in afﬁnity at 10◦C( T a b l e3 ,
Figure 9A).
TodetermineifnucleotidebindingattheNBDaltersthebinding
afﬁnityforlipidA(andviceversa),adualtitrationexperimentwas
performed with lipid A and ATP at 10◦C (to prevent ATP hydro-
lysis), and with lipid A and the non-hydrolysable analogue,
p[NH]ppA, at 23 ◦C. Results showed that MsbA binding afﬁnity
for lipid A was reduced considerably, ∼8-fold, when ATP was
pre-bound at 10◦C, and was ∼3-fold lower when p[NH]ppA
was pre-bound at 23◦C (Table 3, Figure 9C). In contrast, the
MsbAbindingafﬁnityforbothATPandp[NH]ppAwasrelatively
unaffected by lipid A pre-binding (Table 3, Figure 9D). Similar
results were obtained for binding of ATP with vinblastine or
daunorubicin (results not shown). In each case, prior binding of
nucleotide reduced the binding afﬁnity of drug.
Dynamicquenchingwasusedtodeterminetheaqueousaccess-
ibilityofMIANSwithinMsbA.Thisapproachcanalsoprovidein-
formation on conformational changes taking place within the
region close to the labelled cysteine residue following nucleotide
and substrate binding [33]. Three collisional quenchers were
employed; acrylamide (neutral), iodide ion (negative) and cesium
ion(positive).QuenchingofMsbA–MIANSwascarriedoutinthe
presence of ATP and either lipid A or vinblastine, and compared
with results obtained in the absence of drug or nucleotide. All the
Stern–Volmer plots were linear, and no signiﬁcant changes in
theStern–Volmerquenchingconstant,KSV,wereobserved(results
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Figure 9 Sequential binding of lipid A, daunorubicin and nucleotides to MsbA
Dual sequential titrations of MsbA–MIANS in 0.05% DM buffer with lipid A, daunorubicin and p[NH]ppA (AMP-PNP) were performed at 23◦C, with ﬂuorescence emission monitored at 420nm
(λex =322nm). Titration with (A) lipid A and then daunorubicin, (B) daunorubicin and then lipid A, (C) p[NH]ppA and then lipid A, (D) lipid A and then p[NH]ppA. The continuous lines represent
the best computer-generated ﬁt of the data points to an equation describing interaction with a single type of binding site, and were used to estimate the Kd of binding. Data points are the means of
three experiments.
Table 3 Parameters for ﬂuorescence quenching of MsbA–MIANS upon
sequential binding of lipid A, daunorubicin and nucleotides
Dual titration experiments were performed at 23◦Co r1 0 ◦C (*) in which MsbA (100μg/ml)
in Hepes buffer containing 0.05% (w/v) DM was titrated ﬁrst with one substrate and then with
a second, in each of two possible sequences. Corrected ﬂuorescence intensities were ﬁtted to a
single binding-site model using non-linear regression and values for Kd and  Fmax were
estimated. aData are taken from Table 2.
Maximal quenching
Ligand Kd (μM) ( Fmax/F0 ×100) (%)
Lipid A a5.46+ −1.04 a7.32+ −0.49
after daunorubicin 24.5+ −4.4 15.7+ −1.4
after p[NH]ppA 16.4+ −3.7 10.9+ −1.2
Lipid A* 2.44+ −0.35 6.02+ −0.11
after daunorubicin* 18.1+ −3.3 7.31+ −0.50
after ATP* 18.7+ −3.3 17.7+ −1.0
Daunorubicin a4.60+ −0.20 a59.9+ −4.4
after lipid A 4.42+ −0.33 50.9+ −1.5
Daunorubicin* 2.97+ −0.23 60.6+ −0.76
after lipid A* 5.03+ −0.11 63.8+ −0.64
after ATP* 9.59+ −0.39 72.2+ −1.5
ATP* a3050+ −430 a10.9+ −0.75
after lipid A* 2030+ −300 12.0+ −0.78
after daunorubicin* 950+ −230 5.45+ −0.41
p[NH]ppA a470+ −30 a14.1+ −0.3
after lipid A 650+ −80 23.2+ −1.2
not shown), suggesting that the conformational rearrangements
taking place following binding of ATP and substrates do not
change the accessibility of the bound MIANS group.
DISCUSSION
More than 15 years have passed since MsbA ﬁrst attracted
attention as an essential E. coli transporter involved in the lipid
A biosynthetic pathway [39]. However, there is still very limited
biochemical and structural information available for this protein,
whichisgenerallyconsideredtobealipidAﬂippase.Theinherent
difﬁculty in purifying functionally-active membrane proteins in
sufﬁcient quantities for further analysis is partly responsible for
this situation. Site-directed ﬂuorescent labelling is a powerful
approach to provide insights into the processes occurring in ABC
proteins upon substrate binding and transport, as well as nucleo-
tide binding and hydrolysis. Fluorescence spectroscopy is very
sensitive, requiring only small amounts of material, and can
provide information on both protein conformation and dynamics.
The present study is the ﬁrst to report site-speciﬁc ﬂuorescent la-
bellingofpuriﬁedMsbAonacysteineresidue.CDthermaldenat-
uration experiments and ﬂuorescence spectra before and after de-
naturation revealed that MsbA–MIANS maintained its secondary
structure and native folding. Puriﬁed His6-tagged MsbA showed
high ATPase activity that was retained following MIANS labell-
ing. The small loss of MsbA ATPase activity upon MIANS
labelling might arise from protein handling during the labelling
procedure. On the other hand, the ICD containing Cys
315 might be
involved in transmitting a signal for transport between the NBD
andtheTMdomain.CovalentmodiﬁcationofCys
315 couldpoten-
tiallyinﬂuenceinteractionsbetweentheTMdomainandtheNBD,
and in this way affect the intrinsic catalytic activity of the protein.
One MIANS group was incorporated per MsbA monomer,
and experiments using site-directed mutations and MALDI–TOF
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analysis indicated that of the two native cysteine residues,
Cys
315 was modiﬁed. The ﬂuorescence emission spectrum of
MsbA–MIANS displayed a single-component spectrum, with no
evidence of broadening, suggesting that the MIANS-modiﬁed
cysteine residues are in virtually identical local environments in
the MsbA dimer, as expected from the crystal structure. Similar
symmetry was noted for Pgp labelled with MIANS on cysteine
residues within both NBDs [32]. The labelled Cys
315 is located in
the cytoplasmic extension of TM helix 6, within the ICD, and is
predicted to be more accessible to solvent when compared with
Cys
88, which is found in the middle of TM helix 2, close to the
membrane boundary [15]. Utilizing a site-directed mutagenesis
approach and accessibility measurements by EPR spectroscopy,
Dong et al. [21] showed that TM helix 2 is in direct contact
with the lipid bilayer. They found that the aqueous accessibility
of residues in this helix is signiﬁcant up to residue 82, but then
gradually decreases [21]. TM helix 2 of MsbA in detergent
solution is clearly highly shielded from reaction with MIANS,
even in the absence of a membrane bilayer. Therefore, the region
of the helix containing Cys
88 is either protected by lipid/detergent
molecules (if it faces the outer edge of the helix bundle), or is
protected by other protein helices (if it does not). In contrast, the
ICD and residues closest to the C-terminal end of helix 6 were
proposed to have loose packing, since they displayed signiﬁcant
aqueous accessibility. Klug and co-workers also reported that
an EPR probe linked to Cys
315 was relatively mobile compared
with other locations in the protein [22]. The ﬂuorescent labelling
pattern we obtained is consistent with this structural data.
The emission spectrum of MsbA–MIANS provides important
informationonthelocalenvironmentofthemodiﬁedCysresidue.
The relatively large 25 nm blue shift observed when com-
pared with MIANS–DTE suggests that Cys
315 is located in a
hydrophobic environment. A blue shift of similar magnitude was
noted for MIANS-labelled cysteine residues in Pgp and lactose
permease [32,40]. This nonpolar milieu might be provided by
detergent molecules surrounding the protein or by the neigh-
bouringhelixresiduesoftheICDitself.Interestingly,whenMsbA
is aligned with its homologue, LmrA, Cys
315 is located close to
Glu
314 of LmrA. This residue was also found to be located in a
hydrophobic region within LmrA [41], which probably
corresponds to the nonpolar environment we observe for MsbA.
The dimeric MsbA protein may transiently adopt an asym-
metric conformation during the catalytic cycle, as proposed for
Pgp [42], with one of the NBDs containing a tightly-bound
(occluded)nucleotide,andtheotheramoreloosely-boundnucleo-
tide. However, the MIANS group is not located within the NBD
itself, and it is not known whether the other domains of ABC
proteins also develop asymmetry during ATP turnover. It should
also be kept in mind that the asymmetric state of Pgp only
appears to be formed under particular circumstances; during
active ATP hydrolysis (transient), in catalytically inactive
mutants in the presence of nucleotide, and in the presence of the
non-hydrolysable ATP analogue, ATP[S] [43] (in the later two
cases, it is a relatively stable “arrested” state). In the experiments
we describe here, only drug binding is being observed; no
nucleotide is added, and no catalytic turnover takes place, so we
would not expect NBD asymmetry to develop.
Several drugs as well as lipid A greatly reduced the initial rate
of labelling of MsbA with MIANS. Thus binding of substrates
appearstoaltertheaccessibilityorreactivityofCys
315 tolabelling
with the ﬂuorophore. This might be a direct effect of ligand bind-
ing (e.g. steric blocking) if Cys
315 is located close to the drug-
binding site, and the differences observed for the various
drugs could reﬂect the fact that they interact with different
sub-sites within a large ﬂexible substrate-binding pocket.
Alternatively,bindingofsubstratescouldinduceaconformational
change in MsbA, and thus indirectly alter the accessibility or
reactivity of Cys
315 to labelling by MIANS.
Titration of MsbA–MIANS with several drugs and lipid A
resulted in saturable quenching, suggesting that these compounds
bindtotheprotein.Theestimateddissociationconstants(Table2)
showed that drugs bound to MsbA with afﬁnities in the range
0.35–9 μM;severalboundwithafﬁnitycomparablewiththatseen
for lipid A. The binding afﬁnities of MsbA for binding lipid A
and vinblastine were previously determined by quenching of the
intrinsic Trp ﬂuorescence of the protein [14], and similar values
were found to those estimated here from MIANS ﬂuorescence
quenching. Changes in MIANS ﬂuorescence intensity and
emission maximum following ligand binding can result from a
direct effect when the ﬂuorophore is situated very close to the
binding site, or an indirect effect when conformational changes
in other regions of the protein are transmitted to the ﬂuorophore.
The Pgp drug-binding pocket was previously mapped to the
interfacial zone of the cytoplasmic leaﬂet [44,45], which overlaps
with the region where Cys
315 is located. Cys
315 may thus be
positioned close to the site where drugs bind, explaining the high
degree of ﬂuorescence quenching by some compounds. Lipid A
and certain drugs (e.g. verapamil and vinblastine) were reported
to modulate MsbA ATPase activity [7,14], and more work will
be needed to clarify the relationship between drug binding and
ATPase activity. All drugs found to interact with MsbA in this
studyareknownsubstratesofotherMDRtransporters,suchasPgp
and LmrA, which recognize and transport a plethora of chemical
species,manyofwhicharepositivelycharged.WetitratedMsbA–
MIANS with several negatively charged drugs; including the β-
lactam antibiotic ampicillin, and the ﬂuoroquinolone antibiotics,
norﬂoxacin, ciproﬂoxacin and oﬂoxacin. No concentration-
dependent quenching of MIANS ﬂuorescence was observed,
suggesting that these compounds do not interact with MsbA.
For Pgp, two drug-binding sites have been suggested based on
cross-linking studies [46], biphasic quenching curves for some
drugs [47] and dual ﬂuorescence titrations [48]. The presence
of two drug-binding sites was also proposed for LmrA [49]. The
resultsofdualtitrationexperimentsusingMsbAshowedthatlipid
A and daunorubicin are capable of binding to the protein simul-
taneously, regardless of the order in which they are presented,
implying that at least two distinct binding sites exist. Comparison
ofthebindingafﬁnitiesforlipidAanddaunorubicinwhenthetwo
compounds were presented to the protein in an ordered fashion
indicatedthatthetwobindingsitesengageincomplexinteractions
with each other. Lipid A binding afﬁnity is reduced almost 5-fold
when it binds after daunorubicin. In contrast, the binding afﬁnity
for daunorubicin after pre-binding of lipid A is reduced only
at 10◦C; no difference is seen at 23 ◦C. Thus lipid A binding
afﬁnity is negatively regulated by occupation of the other site by
daunorubicin. Similar modulation of the binding afﬁnity of one
substrate by another during sequential binding was previously
observed for Pgp [35,48,50]. Kimura et al. [51] proposed that the
substrate-bindingsiteofABCproteinsthataredualdrugandlipid
transporters is able to accommodate both a drug molecule and a
cholesterol molecule, which they suggested might be involved in
drug recognition. However, a recent study of cholesterol effects
on Pgp-mediated drug binding and transport found no evidence
to support this idea [52]. Our results do not distinguish between
the two possibilities that lipid A and daunorubicin bind to unique
allosterically linked sites, or to overlapping sub-sites within a
large substrate-binding pocket. For Pgp, it has been proposed that
TM helices from both halves of the protein form a large single
drug-binding region which can accommodate multiple substrates
by induced ﬁt [53]. The existence of such a site explains the
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broad substrate speciﬁcity of Pgp, and a similar concept may be
applicable to MsbA, which also binds multiple substrates.
Transport mediated by ABC proteins is an energy-dependent
event, during which conformational changes are transmitted
between the NBDs and the TM domains. The precise order of the
events that drive substrate transport is still under debate. Thus
the ATP switch model proposes that the conformational changes
associated with ATP binding are sufﬁcient to switch the sub-
strate-binding site from high to low afﬁnity, thus releasing the
substrate on the other side of the membrane [54]. Alternatively,
ATP hydrolysis is the driving force for substrate transport [34].
The pump is re-set by either ATP hydrolysis or the exchange of
ADP for ATP. The question of whether ATP binding is sufﬁcient
to trigger the high-afﬁnity to low-afﬁnity switch can be explored
by analysing how ATP binding inﬂuences lipid A-binding
afﬁnity. Thus, in the sequential titration of MsbA with ATP or its
non-hydrolysable analogue p[NH]ppA, and lipid A, it was been
observed that the afﬁnity of lipid A binding is reduced by only 3-
to 8-fold when nucleotide is pre-bound, which is unlikely to be
large enough to trigger dissociation of the lipid. Interestingly, a
comparable reduction in lipid A binding afﬁnity (4- to 7-fold) is
observedwhendaunorubicinisboundﬁrst,suggestingthatsimilar
structural rearrangements may be taking place. We also observed
that if ATP or p[NH]ppA bind after lipid A, their afﬁnities are
not substantially altered. Our results clearly show that binding of
nucleotide and transport substrate to MsbA is not ordered.
Tombline et al. [42] reported that a single occluded ATP
molecule is tightly bound in one NBD of the double catalytic
carboxylate mutant of Pgp (E552A/E1197A). Recently, it has
also been reported that binding of the non-hydrolysable ATP
analogue,ATP[S],toPgppromotestheformationofthisoccluded
state [43]. The binding afﬁnity of the occluded state of Pgp for
ATP[S] is in the low μM range as measured by ﬂuorescence
quenching (A. Siarheyeva, R. Liu and F. J. Sharom, unpublished
work), similar to that observed here for MsbA. It seems likely
that the asymmetric occluded state, where the two NBDs display
tight associations with a single nucleotide molecule, is a common
featureinthecatalyticpathwayofMsbAandotherABCproteins.
Since there are two MIANS groups per homodimer, the observed
ﬂuorescence signal will be an average of both of them. It is not
currently known whether the other domains of ABC proteins also
develop asymmetry during ATP turnover. If they do not, then it is
unlikely that the spectral properties of the two MIANS probes in
MsbAwouldreﬂectdifferencesbetweenthetwomonomersinthe
asymmetric state, since MIANS is located outside the NBDs.
The occluded state of Pgp only appears to be formed under parti-
cularcircumstances;duringactiveATPhydrolysis,incatalytically
inactive mutants in the presence of nucleotide, and following
binding of ATP[S]. In the experiments we describe in the present
study, only drug and nucleotide binding is being observed and
no catalytic turnover of nucleotide takes place, so we would not
expect NBD asymmetry to develop in MsbA–MIANS.
The lipid A export system is a potential target for the
development of novel antibiotics. Since MsbA is one of the rare
transporters identiﬁed as being directly involved in the transport
of lipid species, the identiﬁcation of small molecules capable of
interacting with this protein is of great importance. In addition
to identifying drugs capable of interacting with MsbA, details
of the conformational changes induced by ligand binding are
also needed. The availability of puriﬁed, ﬂuorescently labelled,
catalytically active MsbA lays the groundwork for these types of
studies. The results presented here and previously [14] strongly
suggest that MsbA can bind multiple drugs, and may be both a
lipid ﬂippase and drug transporter. Thus MsbA may resemble
other ABC proteins including LmrA [55], MRP1 (ABCC1) [56],
Pgp [57,58], and its close relative MDR3 (ABCB4) [59], which
function as both drug efﬂux pumps and outward translocators of
membrane lipids. The mechanism by which drugs are extruded
from cells may be closely related to lipid ﬂippase activity, and
lipid and drug translocation may take place through the same
path [57,58,60]. It is possible that these proteins were originally
involved in the transport of lipid derivatives, however during
evolutiontheybecameengagedinthetransportofothersubstrates
sharing physicochemical properties with lipids, and in this way
fulﬁlled an additional protective function in the cell.
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